Zafar Zafari1, Don D Sin2, Dirkje S Postma1, Claes-Göran Löfdahl1, Judith Vonk1, Stirling Bryan1, Stephen Lam1, C Martin Tammemagi1, Rahman Khakban1, S F Paul Man1, Donald Tashkin1, Robert A Wise1, John E Connett1, Bruce McManus1, Raymond Ng1, Zsuszanna Hollander1, Mohsen Sadatsafavi1. 1. Centre for Clinical Epidemiology and Evaluation (Zafari, Bryan, Sadatsafavi), Vancouver Coastal Health Research Institute, University of British Columbia; Centre for Heart and Lung Innovation (Sin, Man, McManus, Hollander), St. Paul's Hospital; Institute for Heart and Lung Health (Sin, Man, McManus, Hollander, Sadatsafavi), University of British Columbia; Division of Respiratory Medicine (Sin, Lam, Man, Sadatsafavi), Department of Medicine, University of British Columbia, Vancouver, BC; University Medical Center Groningen (Postma, Vonk), Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen; University Medical Center Groningen (Postma), Department of Pulmonary Diseases, University of Groningen, Groningen, the Netherlands; Department of Respiratory Medicine and Allergology (Löfdahl), Lund University, Lund, Sweden; Department of Epidemiology (Vonk), University of Groningen, University Medical Center Groningen, the Netherlands; School of Population and Public Health (Bryan), University of British Columbia, Vancouver, BC; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences (Khakban), University of British Columbia, Vancouver, BC; David Geffen School of Medicine at UCLA (Tashkin), Los Angeles, Calif.; Johns Hopkins University School of Medicine (Wise), Baltimore, Md.; University of Minnesota School of Public Health (Connett), Minneapolis, Minn.; PROOF Centre for Excellence (McManus, Ng, Hollander), Vancouver, BC; Department of Community Health Sciences (Tammemagi), Brock University, St. Catharines, Ont. 2. Centre for Clinical Epidemiology and Evaluation (Zafari, Bryan, Sadatsafavi), Vancouver Coastal Health Research Institute, University of British Columbia; Centre for Heart and Lung Innovation (Sin, Man, McManus, Hollander), St. Paul's Hospital; Institute for Heart and Lung Health (Sin, Man, McManus, Hollander, Sadatsafavi), University of British Columbia; Division of Respiratory Medicine (Sin, Lam, Man, Sadatsafavi), Department of Medicine, University of British Columbia, Vancouver, BC; University Medical Center Groningen (Postma, Vonk), Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen; University Medical Center Groningen (Postma), Department of Pulmonary Diseases, University of Groningen, Groningen, the Netherlands; Department of Respiratory Medicine and Allergology (Löfdahl), Lund University, Lund, Sweden; Department of Epidemiology (Vonk), University of Groningen, University Medical Center Groningen, the Netherlands; School of Population and Public Health (Bryan), University of British Columbia, Vancouver, BC; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences (Khakban), University of British Columbia, Vancouver, BC; David Geffen School of Medicine at UCLA (Tashkin), Los Angeles, Calif.; Johns Hopkins University School of Medicine (Wise), Baltimore, Md.; University of Minnesota School of Public Health (Connett), Minneapolis, Minn.; PROOF Centre for Excellence (McManus, Ng, Hollander), Vancouver, BC; Department of Community Health Sciences (Tammemagi), Brock University, St. Catharines, Ont. Don.Sin@hli.ubc.ca.
Abstract
BACKGROUND: The rate of lung-function decline in chronic obstructive pulmonary disease (COPD) varies substantially among individuals. We sought to develop and validate an individualized prediction model for forced expiratory volume at 1 second (FEV1) in current smokers with mild-to-moderate COPD. METHODS: Using data from a large long-term clinical trial (the Lung Health Study), we derived mixed-effects regression models to predict future FEV1 values over 11 years according to clinical traits. We modelled heterogeneity by allowing regression coefficients to vary across individuals. Two independent cohorts with COPD were used for validating the equations. RESULTS: We used data from 5594 patients (mean age 48.4 yr, 63% men, mean baseline FEV1 2.75 L) to create the individualized prediction equations. There was significant between-individual variability in the rate of FEV1 decline, with the interval for the annual rate of decline that contained 95% of individuals being -124 to -15 mL/yr for smokers and -83 to 15 mL/yr for sustained quitters. Clinical variables in the final model explained 88% of variation around follow-up FEV1. The C statistic for predicting severity grades was 0.90. Prediction equations performed robustly in the 2 external data sets. INTERPRETATION: A substantial part of individual variation in FEV1 decline can be explained by easily measured clinical variables. The model developed in this work can be used for prediction of future lung health in patients with mild-to-moderate COPD. TRIAL REGISTRATION: Lung Health Study - ClinicalTrials.gov, no. NCT00000568; Pan-Canadian Early Detection of Lung Cancer Study - ClinicalTrials.gov, no. NCT00751660.
BACKGROUND: The rate of lung-function decline in chronic obstructive pulmonary disease (COPD) varies substantially among individuals. We sought to develop and validate an individualized prediction model for forced expiratory volume at 1 second (FEV1) in current smokers with mild-to-moderate COPD. METHODS: Using data from a large long-term clinical trial (the Lung Health Study), we derived mixed-effects regression models to predict future FEV1 values over 11 years according to clinical traits. We modelled heterogeneity by allowing regression coefficients to vary across individuals. Two independent cohorts with COPD were used for validating the equations. RESULTS: We used data from 5594 patients (mean age 48.4 yr, 63% men, mean baseline FEV1 2.75 L) to create the individualized prediction equations. There was significant between-individual variability in the rate of FEV1 decline, with the interval for the annual rate of decline that contained 95% of individuals being -124 to -15 mL/yr for smokers and -83 to 15 mL/yr for sustained quitters. Clinical variables in the final model explained 88% of variation around follow-up FEV1. The C statistic for predicting severity grades was 0.90. Prediction equations performed robustly in the 2 external data sets. INTERPRETATION: A substantial part of individual variation in FEV1 decline can be explained by easily measured clinical variables. The model developed in this work can be used for prediction of future lung health in patients with mild-to-moderate COPD. TRIAL REGISTRATION: Lung Health Study - ClinicalTrials.gov, no. NCT00000568; Pan-Canadian Early Detection of Lung Cancer Study - ClinicalTrials.gov, no. NCT00751660.
Authors: Annette McWilliams; Martin C Tammemagi; John R Mayo; Heidi Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D Berg; Ken Evans; Richard Finley; John Yee; John English; Paola Nasute; John Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R Johnston; Daria Manos; Garth Nicholas; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern; Rick Bhatia; Ming-Sound Tsao; Stephen Lam Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Janice M Leung; John Mayo; Wan Tan; C Martin Tammemagi; Geoffrey Liu; Stuart Peacock; Frances A Shepherd; John Goffin; Glenwood Goss; Garth Nicholas; Alain Tremblay; Michael Johnston; Simon Martel; Francis Laberge; Rick Bhatia; Heidi Roberts; Paul Burrowes; Daria Manos; Lori Stewart; Jean M Seely; Michel Gingras; Sergio Pasian; Ming-Sound Tsao; Stephen Lam; Don D Sin Journal: Eur Respir J Date: 2015-01-22 Impact factor: 16.671
Authors: N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara Journal: JAMA Date: 1994-11-16 Impact factor: 56.272
Authors: Robab Kohansal; Pablo Martinez-Camblor; Alvar Agustí; A Sonia Buist; David M Mannino; Joan B Soriano Journal: Am J Respir Crit Care Med Date: 2009-04-02 Impact factor: 21.405
Authors: Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard Journal: N Engl J Med Date: 2011-09-26 Impact factor: 91.245
Authors: Kate M Johnson; Mohsen Sadatsafavi; Amin Adibi; Larry Lynd; Mark Harrison; Hamid Tavakoli; Don D Sin; Stirling Bryan Journal: Appl Health Econ Health Policy Date: 2020-11-02 Impact factor: 2.561
Authors: Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2022-02-01 Impact factor: 21.405
Authors: Adel Boueiz; Zhonghui Xu; Yale Chang; Aria Masoomi; Andrew Gregory; Sharon M Lutz; Dandi Qiao; James D Crapo; Jennifer G Dy; Edwin K Silverman; Peter J Castaldi Journal: Chronic Obstr Pulm Dis Date: 2022-07-29
Authors: Marjan Kerkhof; Jaco Voorham; Paul Dorinsky; Claudia Cabrera; Patrick Darken; Janwillem W H Kocks; Mohsen Sadatsafavi; Don D Sin; Victoria Carter; David B Price Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-08-06
Authors: Kate M Johnson; Abdollah Safari; Wan C Tan; Jean Bourbeau; J Mark FitzGerald; Mohsen Sadatsafavi; On Behalf Of The Canadian Cohort Of Obstructive Lung Disease CanCOLD Study Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-12-13
Authors: Alvar Agustí; Albert Compte; Rosa Faner; Judith Garcia-Aymerich; Guillaume Noell; Borja G Cosio; Robert Rodriguez-Roisin; Bartolomé Celli; Josep Maria Anto Journal: PLoS One Date: 2017-10-10 Impact factor: 3.240